Recombinant Cynomolgus Fas/CD95 Protein (HEK293)，hFc

Fas/CD95, a member of the tumor necrosis factor (TNF) receptor superfamily, plays a critical role in regulating apoptosis, immune response, and cellular homeostasis. The Fas receptor is primarily expressed on the surface of various immune cells and is known to mediate programmed cell death upon binding to its ligand, Fas ligand (FasL). Dysregulation of the Fas/FasL pathway has been implicated in a variety of pathological conditions, including autoimmune diseases, cancer, and viral infections. In particular, tumors may exploit this pathway to evade immune detection by expressing FasL, leading to the apoptosis of effector T cells. Consequently, understanding the structural and functional aspects of Fas/CD95 and its interactions can provide insight into its role in these diseases. Research involving recombinant Fas/CD95 proteins has been pivotal in elucidating the mechanistic pathways underlying its signaling. For instance, studies have investigated the receptor's engagement with its ligand and the subsequent activation of apoptotic cascades, as well as the potential for therapeutic interventions that can modulate this pathway. Investigating the recombinant forms of Fas/CD95 not only broadens our comprehension of its biological functions but also holds potential for developing novel strategies to manipulate apoptotic signaling in various clinical settings. Therefore, the study of Fas/CD95 recombinant proteins is of significant importance in the field of immunology and cancer research, as it opens avenues for the development of targeted therapies that can enhance the immune response against tumors while restoring the balance of apoptosis in autoimmune disorders.